KPV

What it is

α-melanocyte-stimulating hormone is a thirteen-residue peptide derived from proopiomelanocortin. It has two separable properties: it drives pigmentation, and it is potently anti-inflammatory. For treating inflammation, the pigmentary effect is an obstacle — which is why researchers looked at whether the anti-inflammatory activity could be isolated.

It can. KPV is the C-terminal tripeptide, residues 11 to 13 of α-MSH. A major review of the field describes it as having been delineated as an alternative for anti-inflammatory therapy precisely because it retains the anti-inflammatory effect but lacks the pigmentary action. Its physicochemical properties and expected low cost of production were explicitly noted as making it attractive for development.

What it does in the body

The mechanistic work here is unusually specific for such a small molecule.

It gets into cells through a transporter. KPV is taken up by PepT1, a di- and tripeptide transporter normally expressed in the small intestine and induced in the colon during inflammatory bowel disease. That induction is convenient: the transporter that carries the drug appears where the disease is. Uptake was confirmed using radiolabelled KPV and competition experiments in human intestinal epithelial cell lines and in human T cells.

It acts at very low concentrations. Nanomolar concentrations inhibited activation of NF-κB and MAP kinase inflammatory signalling and reduced pro-inflammatory cytokine secretion. Nanomolar activity in a tripeptide is notable.

It does not need the melanocortin receptor. In mice engineered with a non-functional melanocortin-1 receptor, KPV treatment still rescued all treated animals from death during chemically induced colitis — indicating the anti-inflammatory effect is at least partly independent of MC1R signalling.

What the human evidence shows

None. There is no published clinical trial of KPV in humans, for any indication. The animal and cell work is genuinely good; the human column is empty.

What exists in human systems:

• Cell studies in human intestinal epithelial lines and human T cells showing PepT1-mediated uptake and anti-inflammatory signalling.
• Work in human bronchial epithelial cells on melanocortin-related peptides and the mechanism of KPV action.
• Signalling studies in human keratinocytes.
• A formulation study on transdermal iontophoretic delivery of KPV across microporated human skin — a delivery experiment on excised skin, not a treatment study.

In animals, oral KPV in drinking water reduced the incidence of both dextran-sulfate and TNBS-induced colitis, with less inflammatory infiltrate on histology and reduced myeloperoxidase activity. In a transfer-colitis model it produced recovery and weight regain. Later work loaded KPV into hyaluronic-acid-functionalised nanoparticles in a hydrogel to target colonic delivery in mice, with better results than the un-targeted formulation — a sign that researchers consider delivery, not activity, the main obstacle.

Claims and what backs them

Risks and unknowns

Complete absence of human data. That is the dominant fact. No pharmacokinetics, no dose-finding, no safety database, no trial of any size.

Immunosuppression is the mechanism. KPV works by damping NF-κB and MAP kinase signalling and reducing pro-inflammatory cytokines. That is desirable in active colitis under supervision. In a healthy person it means blunting the inflammatory response that handles infection, with no data on magnitude or duration.

Delivery is unsolved. The research trajectory — from free peptide, to nanoparticles, to hydrogel-encapsulated targeted nanoparticles — exists because getting KPV where it needs to be at the right concentration is hard. Products sold as KPV do none of this.

The regulator’s objection applies. KPV was one of the peptides for which FDA staff described the evidence as insufficient, and the broader identity-and-manufacturing concerns about compounded peptides apply. One committee member who voted against it described it as “kind of like a black box to me”.

Where regulators stand

The bottom line

KPV is a well-designed idea with good preclinical support and no human testing. The rationale is clean: take the anti-inflammatory tail of a hormone, drop the pigmentation, exploit a transporter that the disease itself upregulates. The mouse colitis data are consistent across models and the nanomolar potency is real.

And after roughly two decades, nobody has given it to a patient in a published trial. The research effort has gone into delivery systems rather than clinical studies, which tells you where the investigators think the difficulty lies. Until someone runs the trial, KPV is a promising hypothesis about inflammatory bowel disease, not a treatment for anything.

References

1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178 PMID 18061177
2. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324–331 PMID 18092346
3. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives. Endocr Rev. 2008;29(5):581–602 PMID 18612139
4. Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628–1640 PMID 28143741
5. Pawar K, Kolli CS, Rangari VK, Babu RJ. Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. J Pharm Sci. 2017;106(7):1814–1820 PMID 28343991